

CITATION REPORT

List of articles citing

Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation

DOI: 10.1097/ftd.ob013e31816337b7

Therapeutic Drug Monitoring, 2008, 30, 46-51.

Source: <https://exaly.com/paper-pdf/44972406/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 54 | Enteric-coated mycophenolate sodium: a review of its use in the prevention of renal transplant rejection. <i>Drugs</i> , 2008 , 68, 2505-33 | 12.1 | 16 |
| 53 | Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. <i>Journal of Clinical Pharmacology</i> , 2009 , 49, 1196-201 | 2.9 | 55 |
| 52 | Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. <i>American Journal of Transplantation</i> , 2009 , 9, 1650-6 | 8.7 | 42 |
| 51 | EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects. <i>Fundamental and Clinical Pharmacology</i> , 2009 , 23, 617-24 | 3.1 | 25 |
| 50 | Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2009 , 28, 605-11 | 5.8 | 39 |
| 49 | New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 416-35 | 3.2 | 124 |
| 48 | Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis. <i>European Journal of Clinical Pharmacology</i> , 2010 , 66, 1119-30 | 2.8 | 17 |
| 47 | Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010 , 5, 341-58 | 6.9 | 226 |
| 46 | Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. <i>Rheumatology</i> , 2010 , 49, 2061-7 | 3.9 | 28 |
| 45 | Enteric-coated mycophenolate sodium. <i>Expert Opinion on Drug Safety</i> , 2010 , 9, 981-94 | 4.1 | 34 |
| 44 | The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. <i>Clinical Pharmacokinetics</i> , 2011 , 50, 1-24 | 6.2 | 41 |
| 43 | The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2011 , 30, 565-71 | 5.8 | 21 |
| 42 | The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR study. <i>Therapeutic Drug Monitoring</i> , 2011 , 33, 120-3 | 3.2 | 15 |
| 41 | Renal graft function and low-dose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantation. <i>Transplantation</i> , 2011 , 92, 550-6 | 1.8 | 6 |
| 40 | Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011 , 36, 208-16 | 2.2 | 9 |
| 39 | Mycophenolic acid in kidney transplant patients with diabetes mellitus: does the formulation matter?. <i>Transplantation Reviews</i> , 2011 , 25, 117-23 | 3.3 | 7 |
| 38 | Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting. <i>Transplantation Reviews</i> , 2011 , 25, 58-64 | 3.3 | 52 |

| | | | |
|----|--|-----|----|
| 37 | Update on the pharmacogenomics of proton pump inhibitors. <i>Pharmacogenomics</i> , 2011 , 12, 873-88 | 2.6 | 57 |
| 36 | Diminished mycophenolic acid exposure caused by omeprazole may be clinically relevant in the first week posttransplantation. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 331-6 | 3.2 | 9 |
| 35 | Evaluation of potential interactions between mycophenolic acid derivatives and proton pump inhibitors. <i>Annals of Pharmacotherapy</i> , 2012 , 46, 1054-64 | 2.9 | 14 |
| 34 | Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. <i>Transplantation</i> , 2012 , 94, 1013-9 | 1.8 | 44 |
| 33 | Lansoprazole-induced acute allergic interstitial nephritis in a renal transplant recipient: a case report. <i>International Urology and Nephrology</i> , 2012 , 44, 1903-6 | 2.3 | 5 |
| 32 | Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. <i>Journal of Clinical Pharmacology</i> , 2012 , 52, 1265-72 | 2.9 | 35 |
| 31 | Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing. <i>Transplantation Reviews</i> , 2012 , 26, 233-40 | 3.3 | 14 |
| 30 | Pharmacokinetic and Pharmacodynamic Properties of Mycophenolate. 2012 , 182-196 | | |
| 29 | Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 303-31 | 6.2 | 47 |
| 28 | Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. <i>British Journal of Clinical Pharmacology</i> , 2013 , 75, 463-75 | 3.8 | 23 |
| 27 | Kidney Transplantation. 2014 , | | 2 |
| 26 | Drug Interactions in Organ Transplantation. 2014 , 1242-1255 | | |
| 25 | Concomitant proton pump inhibitors with mycophenolate mofetil and the risk of rejection in kidney transplant recipients. <i>Transplantation</i> , 2014 , 97, 518-24 | 1.8 | 20 |
| 24 | No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 1086-96 | 3.8 | 10 |
| 23 | Drug-drug interactions related to altered absorption and plasma protein binding: theoretical and regulatory considerations, and an industry perspective. <i>Journal of Pharmaceutical Sciences</i> , 2015 , 104, 916-29 | 3.9 | 16 |
| 22 | Influence of Proton Pump Inhibitors on Mycophenolic Acid Pharmacokinetics in Patients With Renal Transplantation and the Relationship With Cytochrome 2C19 Gene Polymorphism. <i>Transplantation Proceedings</i> , 2017 , 49, 490-496 | 1.1 | 5 |
| 21 | Renal Transplant Acute Rejection with Lower Mycophenolate Mofetil Dosing and Proton Pump Inhibitors or Histamine-2 Receptor Antagonists. <i>Pharmacotherapy</i> , 2017 , 37, 1507-1515 | 5.8 | 5 |
| 20 | Interaction of Mycophenolic Acid and Pantoprazole. 2017 , | | |

| | | | |
|----|---|-----|----|
| 19 | Stereoselective and nonstereoselective pharmacokinetics of rabeprazole - an overview. <i>Xenobiotica</i> , 2018 , 48, 422-432 | 2 | 7 |
| 18 | Longitudinal Pharmacokinetics of Mycophenolic Acid in Elderly Renal Transplant Recipients Compared to a Younger Control Group: Data from the nEverOld Trial. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019 , 44, 189-199 | 2.7 | 4 |
| 17 | High plasma mycophenolate acid concentration in the early phase of induction therapy predicts good renal outcome in lupus nephritis. <i>Modern Rheumatology</i> , 2020 , 30, 517-524 | 3.3 | 2 |
| 16 | Mycophenolic Acid and Its Pharmacokinetic Drug-Drug Interactions in Humans: Review of the Evidence and Clinical Implications. <i>Journal of Clinical Pharmacology</i> , 2020 , 60, 295-311 | 2.9 | 11 |
| 15 | Therapeutic Strategies for Treatment of Immune-Mediated Hemolytic Anemia. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 2020 , 50, 1327-1349 | 2.4 | 4 |
| 14 | Effect of the proton-pump Inhibitor pantoprazole on Mycophenolic Acid exposure in kidney and liver transplant recipients (IMPACT study): a randomized trial. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 1060-1070 | 4.3 | 3 |
| 13 | The Effect of Proton Pump Inhibitor Use on Renal Function in Kidney Transplanted Patients. <i>Journal of Clinical Medicine</i> , 2020 , 9, | 5.1 | 2 |
| 12 | Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2021 , 43, 150-200 | 3.2 | 17 |
| 11 | The Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid: Systematic Review and Meta-analysis. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 1291-1302 ^{6.2} | 6.2 | 3 |
| 10 | Drug Interactions in Solid Organ Transplant Recipients. 2014 , 411-425 | | 1 |
| 9 | The impact of omeprazole on mycophenolate pharmacokinetics in kidney transplant recipients. <i>Kidney Research and Clinical Practice</i> , 2020 , 39, 479-486 | 3.6 | 1 |
| 8 | [Drug interactions and immunosuppression in organ transplant recipients]. <i>Tidsskrift for Den Norske Laegeforening</i> , 2011 , 131, 2000-3 | 3.5 | 7 |
| 7 | High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2013 , 51, 711-7 | 2 | 12 |
| 6 | Proton pump inhibitors and adverse effects in kidney transplant recipients: A meta-analysis. <i>World Journal of Transplantation</i> , 2019 , 9, 35-47 | 2.3 | 5 |
| 5 | CHAPTER 12: Drug-Drug Interactions: Regulatory and Theoretical Considerations, and an Industry Perspective. <i>RSC Drug Discovery Series</i> , 2015 , 263-282 | 0.6 | |
| 4 | Drug-Drug Interactions Between Mycophenolic Acid and Proton Pump Inhibitors: A Systematic Review and Meta-Analysis.. <i>Therapeutic Drug Monitoring</i> , 2021 , | 3.2 | |
| 3 | Population pharmacokinetics of mycophenolate mofetil in pediatric patients early after liver transplantation. 13 , | | 0 |
| 2 | Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of mycophenolate mofetil in Japanese patients with lupus nephritis. 2023 , 9, | | 0 |

1 Systemic Lupus Erythematosus. **2023**, 167-212

o